Eli Lilly and Company (NYSE:LLY) Shares Sold by Ossiam

Ossiam decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 13.9% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 18,337 shares of the company’s stock after selling 2,954 shares during the quarter. Ossiam’s holdings in Eli Lilly and were worth $4,465,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. BlackRock Inc. boosted its holdings in shares of Eli Lilly and by 3.1% during the second quarter. BlackRock Inc. now owns 60,927,657 shares of the company’s stock valued at $13,984,117,000 after acquiring an additional 1,856,395 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Eli Lilly and by 116.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 26,155,001 shares of the company’s stock valued at $4,886,278,000 after acquiring an additional 14,060,388 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Eli Lilly and by 4.2% during the second quarter. Geode Capital Management LLC now owns 13,964,273 shares of the company’s stock valued at $3,196,763,000 after acquiring an additional 564,757 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Eli Lilly and by 5.4% during the first quarter. Bank of New York Mellon Corp now owns 9,787,826 shares of the company’s stock valued at $1,828,562,000 after acquiring an additional 505,780 shares during the period. Finally, Jennison Associates LLC boosted its holdings in shares of Eli Lilly and by 63.8% during the second quarter. Jennison Associates LLC now owns 8,910,995 shares of the company’s stock valued at $2,045,252,000 after acquiring an additional 3,470,858 shares during the period. 81.65% of the stock is owned by institutional investors.

NYSE LLY traded down $1.40 on Thursday, hitting $235.04. 3,788 shares of the company were exchanged, compared to its average volume of 3,457,061. The company’s 50 day moving average price is $247.65 and its 200-day moving average price is $223.58. The company has a debt-to-equity ratio of 2.21, a current ratio of 1.15 and a quick ratio of 0.89. The firm has a market capitalization of $225.41 billion, a P/E ratio of 35.45, a price-to-earnings-growth ratio of 1.86 and a beta of 0.25. Eli Lilly and Company has a twelve month low of $129.21 and a twelve month high of $275.87.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Monday, August 2nd. The company reported $1.87 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.89 by ($0.02). The company had revenue of $6.74 billion for the quarter, compared to analyst estimates of $6.59 billion. Eli Lilly and had a return on equity of 119.12% and a net margin of 22.71%. Eli Lilly and’s quarterly revenue was up 22.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.89 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 7.87 EPS for the current year.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 236,542 shares of the business’s stock in a transaction dated Tuesday, August 3rd. The stock was sold at an average price of $256.12, for a total transaction of $60,583,137.04. Following the sale, the insider now owns 108,537,712 shares in the company, valued at approximately $27,798,678,797.44. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last 90 days, insiders have sold 492,615 shares of company stock worth $128,197,709. Corporate insiders own 0.13% of the company’s stock.

Several equities analysts have recently issued reports on LLY shares. Citigroup raised shares of Eli Lilly and from a “neutral” rating to a “buy” rating and boosted their price target for the company from $210.00 to $265.00 in a report on Wednesday, September 29th. They noted that the move was a valuation call. DZ Bank upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $288.00 price objective on the stock in a research note on Thursday, August 5th. Barclays lifted their price objective on shares of Eli Lilly and from $227.00 to $250.00 and gave the company an “overweight” rating in a research note on Tuesday, July 6th. Mizuho lifted their price objective on shares of Eli Lilly and from $250.00 to $279.00 and gave the company a “buy” rating in a research note on Wednesday, August 4th. Finally, Cantor Fitzgerald lifted their price objective on shares of Eli Lilly and from $245.00 to $300.00 and gave the company an “overweight” rating in a research note on Thursday, June 24th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Eli Lilly and has an average rating of “Buy” and an average target price of $258.22.

About Eli Lilly and

Eli Lilly & Co engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm’s products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity.

Recommended Story: What is a trade deficit?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.